Aminopeptidase inhibitors - Pipeline Insight, 2022
![](/report_cover/8047/aminopeptidase-inhibitors-pipeline-insight-2022_en.gif)
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Aminopeptidase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Aminopeptidase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Aminopeptidase inhibitors: Overview
Aminopeptidases, which are widely distributed in nature, are one of the two major subclasses of the exopeptidases, proteolytic enzymes that remove amino acids from the termini of peptides and proteins (the other being the carboxypeptidases). As the name indicates, the aminopeptidases attack their substrates exclusively from the amino terminal end. Aminopeptidase A (APA), also known as a glutamyl aminopeptidase and CD249, cleaves the N-terminal residue of AngII to form Ang-(2-8), also known as angiotensin-III (AngIII). Methionine aminopeptidase (MetAP) catalyzes the hydrolytic cleavage of the N-terminal methionine from newly synthesized polypeptides.
Report Highlights
This segment of the Aminopeptidase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Aminopeptidase inhibitors Emerging Drugs
Further product details are provided in the report……..
Aminopeptidase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Aminopeptidase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Aminopeptidase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aminopeptidase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aminopeptidase inhibitors drugs.
Aminopeptidase inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Aminopeptidase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Aminopeptidase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Aminopeptidase inhibitors: Overview
Aminopeptidases, which are widely distributed in nature, are one of the two major subclasses of the exopeptidases, proteolytic enzymes that remove amino acids from the termini of peptides and proteins (the other being the carboxypeptidases). As the name indicates, the aminopeptidases attack their substrates exclusively from the amino terminal end. Aminopeptidase A (APA), also known as a glutamyl aminopeptidase and CD249, cleaves the N-terminal residue of AngII to form Ang-(2-8), also known as angiotensin-III (AngIII). Methionine aminopeptidase (MetAP) catalyzes the hydrolytic cleavage of the N-terminal methionine from newly synthesized polypeptides.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Aminopeptidase inhibitors R&D. The therapies under development are focused on novel approaches for Aminopeptidase inhibitors.
This segment of the Aminopeptidase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Aminopeptidase inhibitors Emerging Drugs
- Firibastat: Quantum Genomics
- APL-1202: Asieris Pharmaceuticals
Further product details are provided in the report……..
Aminopeptidase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Aminopeptidase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Aminopeptidase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Aminopeptidase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aminopeptidase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aminopeptidase inhibitors drugs.
Aminopeptidase inhibitors Report Insights
- Aminopeptidase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Aminopeptidase inhibitors drugs?
- How many Aminopeptidase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aminopeptidase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aminopeptidase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Aminopeptidase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Quantum Genomics
- Asieris Pharmaceuticals
- Pharmaleads
- EMD Serono
- SynDevRx, Inc
- Larimar Therapeutics
- Firibastat
- APL-1202
- APL 1501
- PL 37
- PL 265
- M 8891
- SDX 7195
- SDX 7320
- Aclimostat
- QGC-006
Introduction
Executive Summary
Aminopeptidase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Aminopeptidase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Firibastat: Quantum Genomics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
PL 37: Pharmaleads
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
M 8891: EMD Serono
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SDX 7195: SynDevRx, Inc
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Aminopeptidase inhibitors Key Companies
Aminopeptidase inhibitors Key Products
Aminopeptidase inhibitors- Unmet Needs
Aminopeptidase inhibitors- Market Drivers and Barriers
Aminopeptidase inhibitors- Future Perspectives and Conclusion
Aminopeptidase inhibitors Analyst Views
Aminopeptidase inhibitors Key Companies
Appendix
Executive Summary
Aminopeptidase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Aminopeptidase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Firibastat: Quantum Genomics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
PL 37: Pharmaleads
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
M 8891: EMD Serono
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SDX 7195: SynDevRx, Inc
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Aminopeptidase inhibitors Key Companies
Aminopeptidase inhibitors Key Products
Aminopeptidase inhibitors- Unmet Needs
Aminopeptidase inhibitors- Market Drivers and Barriers
Aminopeptidase inhibitors- Future Perspectives and Conclusion
Aminopeptidase inhibitors Analyst Views
Aminopeptidase inhibitors Key Companies
Appendix